Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

c-Src Antisense Complexed with PAMAM Denderimes Decreases of c-Src Expression and EGFR-Dependent Downstream Genes in the Human HT-29 Colon Cancer Cell Line

  • Nourazarian, Ali Reza (Department of Biochemistry, Faculty of Medicine, Research Center, Kerman University of Medical Sciences) ;
  • Pashaei-Asl, Roghiyeh (Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences) ;
  • Omidi, Yadollah (Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences) ;
  • Najar, Ahmad Gholamhoseinian (Biochemistry Department & Kerman Physiology, Research Center, Kerman University of Medical Sciences)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

c-Src is one member of non-receptor tyrosine kinase protein family that has over expression and activation in many human cancer cells. It has been shown that c-Src is implicated in various downstream signaling pathways associated with EGFR-dependent signaling such as MAPK and STAT5 pathways. Transactivation of EGFR by c-Src is more effective than EGFR ligands. To inhibit the c-Src expression, we used c-Src antisense oligonucleotide complexed with PAMAM Denderimes. The effect of c-Src antisense oligonucleotide on HT29 cell proliferation was determined by MTT assay. Then, the expression of c-Src, EGFR and the genes related to EGFR-depended signaling with P53 was applied by real time PCR. We used western blot analysis to elucidate the effect of antisense on the level of c-Src protein expression. The results showed, c-Src antisense complexed with PAMAM denderimers has an effective role in decrease of c-Src expression and EGFR-dependent downstream genes.

Keywords

References

  1. Baker JR, Bielinska AU, Kukowska-Latallo JF (2004). Dendrimer-mediated cell transfection in vitro. Methods Mol Biol, 245, 67-82.
  2. Chapnick DA, Warner L, Bernet J, et al (2011). the TGF beta and MAPK pathways in cancer progression. Cell Biosci, 1, 42. https://doi.org/10.1186/2045-3701-1-42
  3. Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ ( 2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol, 79, 224-50. https://doi.org/10.1016/j.critrevonc.2010.07.012
  4. Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR (2000). The use of PAMAM Denderimes in the efficient transfer of genetic material into cells. Pharm Sci Technolo Today, 3, 232-45. https://doi.org/10.1016/S1461-5347(00)00273-X
  5. Ellis LM, Staley CA, Liu W, et al (1998). Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem, 273, 1052-7. https://doi.org/10.1074/jbc.273.2.1052
  6. Green DW, Roh H, Pippin JA, Drebin JA (2001). Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res, 101, 16-20. https://doi.org/10.1006/jsre.2001.6241
  7. Greenlee RT, Murray T, Bolden S, Wingo PA (2000). Cancer statistics. CA Cancer J Clin, 50, 7-33. https://doi.org/10.3322/canjclin.50.1.7
  8. Irby RB, Yeatman TJ (2000). Role of Src expression and activation in human cancer. Oncogene, 19, 5636-42. https://doi.org/10.1038/sj.onc.1203912
  9. Kumar R, Srinivasan S, Pahari P, Rohr J, Damodaran C ( 2010). Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol Cancer Ther, 9, 2488-96. https://doi.org/10.1158/1535-7163.MCT-10-0180
  10. Lieu C, Kopetz S (2010). The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clin Colorectal Cancer, 9, 89-94. https://doi.org/10.3816/CCC.2010.n.012
  11. Mao W, Irby R, Coppola D, et al (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene, 15, 3083-90. https://doi.org/10.1038/sj.onc.1201496
  12. Midgley R, Kerr D (1999). colorectal cancer. Lancet, 353, 391-9. https://doi.org/10.1016/S0140-6736(98)07127-X
  13. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54. https://doi.org/10.1016/0003-2697(76)90527-3
  14. Mukhopadhyay D, Tsiokas L, Zhou XM, et al (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature, 375, 577-81. https://doi.org/10.1038/375577a0
  15. Nakhlband A, Barar J, Bidmeshkipour A, Heidari HR, Omidi Y (2010). Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol, 6, 360-9. https://doi.org/10.1166/jbn.2010.1131
  16. Orava EW, Cicmil N, Gariepy J (2010). Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta, 1798, 2190-200. https://doi.org/10.1016/j.bbamem.2010.02.004
  17. Rubenstein M, Tsui P, Guinan P (2010). Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2. Med Oncol, 25, 182-6.
  18. Kopetz S (2007). Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res, 1, 37-41.
  19. Raymond WR (2007). Cancer Biology. 4th ed. Michigan1: University of Michigan Medical School Ann Arbor.
  20. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.
  21. Staley CA, Parikh NU, Gallick GE (1997). Decrasesd tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ, 8, 269-74.
  22. Summy JM, Gallick GE (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev, 22, 337-58. https://doi.org/10.1023/A:1023772912750
  23. Summy JM, Trevino JG, Lesslie DP, et al (2005). AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther, 4, 1900-11. https://doi.org/10.1158/1535-7163.MCT-05-0171
  24. Talamonti MS, Roh MS, Curley SA, Gallick GE (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest, 91, 53-60. https://doi.org/10.1172/JCI116200
  25. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE (1993). Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res, 54, 293-8. https://doi.org/10.1006/jsre.1993.1046
  26. Wang P, Zhao XH, Wang ZY, et al (2010). Generation 4 polyamidoamine dendrimers is a novel candidate of nanocarrier for gene delivery agents in breast cancer treatment. Cancer Lett, 298, 34-49. https://doi.org/10.1016/j.canlet.2010.06.001
  27. Windham TC, Parikh NU, Siwak DR, et al (2002). Src activation regulates anoikis in human colon tumor cell lines. Oncogene, 21, 7797-807. https://doi.org/10.1038/sj.onc.1205989
  28. Xiong H, Su WY, Liang QC, et al (2009). Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest, 89, 717-25. https://doi.org/10.1038/labinvest.2009.11
  29. Yamaguchi M, Tanaka T, Waki M, et al (1997). Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells. Leukemia, 11, 497-503. https://doi.org/10.1038/sj.leu.2400605
  30. Yavari K, Taghikhani M, Maragheh MG, Mesbah-Namin SA, Babaei MH (2009). Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro. Arch Med Res, 40, 235-40. https://doi.org/10.1016/j.arcmed.2009.03.001

Cited by

  1. Preventive and Therapeutic Roles of Ginseng - Focus on Colon Cancer vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.585
  2. Advances in the application of nanotechnology in the diagnosis and treatment of gastrointestinal tumors vol.3, pp.2, 2015, https://doi.org/10.3892/mco.2014.470
  3. Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics vol.12, pp.7, 2015, https://doi.org/10.1517/17425247.2015.1042857